Cytosar

(Cytarabine)

ApprovedSmall molecule

Cytarabine is a chemotherapy drug used to treat certain types of blood cancers like leukemia and lymphoma by stopping cancer cells from growing and dividing.[2] Cytosar is currently approved and in use across 77 indications[4].[1]

Cytosar is one of 1038 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

Indications

929

Total Trials

Active Trials

1,037

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Non-Hodgkins LymphomaApproved

NeutropeniaActive, not recruiting

Adult Acute Lymphoblastic LeukemiaApproved

Meningeal NeoplasmActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Thrombotic DiseaseApproved

Lymphoblastic LymphomaApproved

Unspecified Peripheral T-Cell LymphomaApproved

T-Cell Non-Hodgkin LymphomaActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

NeutropeniaPhase 2

Active, not recruiting

Adult Acute Lymphoblastic LeukemiaApproved

Approved

Meningeal NeoplasmApproved

Active, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Thrombotic DiseaseApproved

Approved

Lymphoblastic LymphomaApproved

Approved

Unspecified Peripheral T-Cell LymphomaApproved

Approved

T-Cell Non-Hodgkin LymphomaPhase 1

Active, not recruiting

Showing 10 of 77 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cytosar

DATROWAY

4 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT02883049

Phase 2Recruiting

Acute Lymphoblastic Leukemia

NCT02877303

Q1 2027

Phase 2Active, not recruiting

Acute Myeloid Leukemia

NCT02392429

Phase 2Recruiting

Relapsed or Refractory

NCT06316960

Phase 2Active, not recruiting

Mantle Cell Lymphoma

NCT03710772

Q2 2027

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT03793478

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia48 trials

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting·SShanxi Bethune Hospital·Phase 3·NCT05726110·50 enrolled

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Not yet recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT07223814·875 enrolled

Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

Terminated·UUniversity of Florida·Phase 2·NCT04914676·5 enrolled

Show 45 more trials

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT02029417·2 enrolled

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Recruiting·UUniversity of Washington·Phase 1/2·NCT04797767·62 enrolled

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

Unknown status·VVion Pharmaceuticals·Phase 2·NCT00354276·85 enrolled

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02392429·87 enrolled

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Completed·UUniversity of Ulm·Phase 2·NCT01477606·451 enrolled

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn·AAVEO Pharmaceuticals, Inc.·Phase 2·NCT04100330

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

Completed·—·Phase 1/2·NCT01690507·29 enrolled

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·NNewLink Genetics Corporation·Phase 1·NCT02835729·54 enrolled

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Unknown status·LLi Junmin·Phase 2·NCT03381781·100 enrolled

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT02791919

Natural Killer Cells in Older Patients With Acute Myeloid Leukemia

Completed·IInstitut Paoli-Calmettes·N/A·NCT00540956·40 enrolled

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 1·NCT01154439·11 enrolled

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Completed·—·Phase 1·NCT02070458·30 enrolled

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00422591·175 enrolled

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Terminated·UUniversity of Washington·Phase 1·NCT04196010·13 enrolled

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Withdrawn·EEmory University·Phase 1·NCT02680951

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02343939·148 enrolled

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Unknown status·PPETHEMA Foundation·Phase 1/2·NCT04112589·63 enrolled

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Terminated·AAntisoma Research·Phase 2·NCT01034410·90 enrolled

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT03182244·276 enrolled

Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Unknown status·IInstitut de Recherche Clinique sur les Cancers et le Sang·Phase 1·NCT00544999·21 enrolled

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00372593·1,070 enrolled

S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00840177·115 enrolled

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00634244·92 enrolled

6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Withdrawn·WWake Forest University Health Sciences·Phase 1/2·NCT02472626

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02583893·39 enrolled

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1/2·NCT00906945·39 enrolled

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01249430·24 enrolled

Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1·NCT00004056·35 enrolled

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Withdrawn·UUniversity of Florida·Phase 2·NCT03207334

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00005863

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Completed·PPETHEMA Foundation·Phase 2·NCT04107727·273 enrolled

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Completed· Novartis logo

Novartis·Phase 3·NCT03379727·301 enrolled

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Completed· Astellas logo

Astellas·Phase 1/2·NCT02310321·97 enrolled

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed· Astellas logo

Astellas·Phase 1·NCT02236013·80 enrolled

Alisertib for Acute Myeloid Leukemia

Completed·MMassachusetts General Hospital·Phase 1·NCT01779843·22 enrolled

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT03793478·65 enrolled

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Completed· AbbVie logo

AbbVie·Phase 3·NCT03069352·211 enrolled

Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

Completed·UUniversity Hospital Muenster·Phase 3·NCT00266136·3,500 enrolled

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Completed·UUniversity of Ulm·Phase 3·NCT01237808·144 enrolled

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Completed·CChildren's Oncology Group·Phase 2·NCT00070174·350 enrolled

S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00049179·33 enrolled

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Completed·AAlison Walker·Phase 1·NCT01174888·34 enrolled

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting·KKura Oncology, Inc.·Phase 1·NCT06001788·171 enrolled

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT06034470·30 enrolled

Acute Lymphoblastic Leukemia30 trials

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Completed·MMehrdad Abedi, MD·Phase 1·NCT02293109·10 enrolled

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01190930·9,350 enrolled

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00671034·166 enrolled

Show 27 more trials

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Completed·CChildren's Oncology Group·Phase 1·NCT00866307·104 enrolled

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00002756·221 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02883049·5,949 enrolled

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT01156883·76 enrolled

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01614197·16 enrolled

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT00440726·31 enrolled

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia

Completed·WWake Forest University Health Sciences·Phase 2·NCT01656031·39 enrolled

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002514·1,929 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01230983·573 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00494897·374 enrolled

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00390793·107 enrolled

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Terminated· Sanofi logo

Sanofi·Phase 2·NCT03860844·67 enrolled

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003728·1,500 enrolled

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00049569·126 enrolled

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03518112·6 enrolled

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

Recruiting·—·Phase 1·NCT05157971·24 enrolled

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02877303·80 enrolled

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005603·276 enrolled

S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00337168·36 enrolled

Lymphoma15 trials

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Completed·PPolish Lymphoma Research Group·Phase 2·NCT01481272·77 enrolled

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00074178·22 enrolled

Show 12 more trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002982

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00080886·68 enrolled

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005998

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00669812·60 enrolled

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01511562·113 enrolled

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005985·213 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Withdrawn·FFred Hutchinson Cancer Center·N/A·NCT01769911

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Completed·TThe Lymphoma Academic Research Organisation·Phase 1·NCT02741388·39 enrolled

Leukemia12 trials

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

Completed·VVirginia Commonwealth University·Phase 2·NCT00017342

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005977·83 enrolled

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05645718·27 enrolled

Show 9 more trials

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Unknown status·FFacet Biotech·Phase 3·NCT00006045

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

Unknown status·GGrupo Argentino de Tratamiento de la Leucemia Aguda·Phase 2/3·NCT00002499

Efficacy and Safety of Chidamide in CBF Leukemia

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03031262·250 enrolled

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Unknown status·HHannover Medical School·Phase 2·NCT00002532

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT02287233·94 enrolled

Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·N/A·NCT01184898·36 enrolled

Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Completed·MMedical Research Council·Phase 2·NCT00040690·120 enrolled

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038610·54 enrolled

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

Completed·VVirginia Commonwealth University·Phase 1·NCT00002818·15 enrolled

Myelodysplastic Syndrome8 trials

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01289457·282 enrolled

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00077116·31 enrolled

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02029950·50 enrolled

Show 5 more trials

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05146739·8 enrolled

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

Completed·UUniversity of Washington·N/A·NCT02121418·12 enrolled

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT02521493·280 enrolled

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01515527·160 enrolled

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Completed·UUniversity of Washington·Phase 2·NCT01101880·50 enrolled

52 more indications

Chronic Myelogenous Leukemia6 trials

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002800·60 enrolled

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00015834·46 enrolled

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002598·30 enrolled

Show 3 more trials

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Completed·HHeidelberg University·Phase 3·NCT00055874·1,551 enrolled

Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00053144

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003694·60 enrolled

Bone Marrow Transplantation6 trials

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002547·280 enrolled

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002502

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00003436·2,000 enrolled

Show 3 more trials

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Completed·VVirginia Commonwealth University·Phase 2/3·NCT00003187·19 enrolled

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002534

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

Chemotherapy5 trials

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Withdrawn·RRush University Medical Center·Phase 2·NCT00003407

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

Terminated· Gilead logo

Gilead·Phase 1·NCT03135028·9 enrolled

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00014495·32 enrolled

Show 2 more trials

Lenalidomide Plus Chemotherapy for AML

Completed·MMassachusetts General Hospital·Phase 1·NCT01681537·36 enrolled

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Recruiting·MMontefiore Medical Center·Phase 1·NCT05342584·99 enrolled

Myelodysplastic Syndromes4 trials

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·N/A·NCT01831232·24 enrolled

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00480987·27 enrolled

Show 1 more trial

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01692197·43 enrolled

Newly Diagnosed4 trials

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting·CChildren's Oncology Group·Phase 3·NCT04293562·1,186 enrolled

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Completed·TThe Catholic University of Korea·Phase 2·NCT01004497·51 enrolled

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06561880·36 enrolled

Show 1 more trial

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Terminated·KKronos Bio·Phase 3·NCT05020665·15 enrolled

Mantle Cell Lymphoma4 trials

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041132·56 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006747·4 enrolled

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00450801·22 enrolled

Show 1 more trial

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03710772·51 enrolled

Stem Cell Transplant3 trials

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No longer available·BBarbara Ann Karmanos Cancer Institute··NCT00423826

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT02483000·3 enrolled

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT06928662·36 enrolled

Hematologic Malignancies3 trials

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT05476770·54 enrolled

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02433483·4 enrolled

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Completed· Pfizer logo

Pfizer·Phase 1·NCT02038777·48 enrolled

Relapse2 trials

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Terminated·—·Phase 3·NCT02366663·3 enrolled

Epigenetic Reprogramming in Relapse AML

Terminated·MMichael Burke·Phase 1·NCT02412475·3 enrolled

Acute Leukemia2 trials

A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT06474663

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01794702·65 enrolled

Treatment2 trials

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

Unknown status·MMichael Luebbert·Phase 1/2·NCT02717884·60 enrolled

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Unknown status·UUniversity of Birmingham·Phase 2/3·NCT04217278·333 enrolled

Acute Promyelocytic Leukemia2 trials

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Completed·TTechnische Universität Dresden·Phase 3·NCT02688140·135 enrolled

Relapsed/Refractory2 trials

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Completed·—·Phase 1·NCT03349281·6 enrolled

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Unknown status·SSwedish Medical Center·Phase 2·NCT03736616·47 enrolled

Stem Cell Transplantation2 trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT00004114

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

Unknown status·—·Phase 1·NCT00004086

Diffuse Large B-Cell Lymphoma2 trials

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

Withdrawn·—·Phase 2·NCT03719560

Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed·WWashington University School of Medicine·Phase 1·NCT03072771·14 enrolled

Relapsed or Refractory2 trials

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Recruiting·—·Phase 2·NCT06316960·50 enrolled

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07032727·68 enrolled

Morbidity1 trial

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

Recruiting·PPeking University People's Hospital·Phase 2·NCT03412409·50 enrolled

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Acute Monocytic Leukemia1 trial

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT05313958·43 enrolled

Immunotherapy1 trial

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Withdrawn·NNorthwestern University·Phase 1·NCT00734773

Elderly Patients1 trial

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06744556·60 enrolled

Transplantation1 trial

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Terminated·WWashington University School of Medicine·Phase 2·NCT00593645·7 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Unknown status·SSun Yat-sen University·Phase 2·NCT04254640·34 enrolled

Maintenance Therapy1 trial

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Completed·UUniversity of Ulm·Phase 2·NCT01180322·277 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04546399·461 enrolled

Anemia1 trial

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·N/A·NCT01350232·2 enrolled

Hematologic Cancer1 trial

Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00015951

Langerhans Cell Histiocytosis1 trial

AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04121819·40 enrolled

ART1 trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Recruiting·KKura Oncology, Inc.·Phase 1·NCT05735184·420 enrolled

Relapsed AML1 trial

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

Completed·EEleos, Inc.·Phase 2·NCT00074737·53 enrolled

Myeloid Neoplasm1 trial

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled

Hematopoietic Stem Cell Mobilization1 trial

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Unknown status·—·N/A·NCT05510089·62 enrolled

Safety and Efficacy1 trial

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07441967·44 enrolled

Secondary AML1 trial

Amonafide in Combination With Cytarabine in Secondary AML

Completed·XXanthus Pharmaceuticals, Inc.·Phase 2·NCT00273884·80 enrolled

Graft-versus-host-disease (GVHD)1 trial

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT00429416·14 enrolled

Induction Chemotherapy1 trial

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Unknown status·AArog Pharmaceuticals, Inc.·Phase 3·NCT03258931·510 enrolled

Central Nervous System Lymphoma1 trial

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT01399372·91 enrolled

Lymphoid Malignancies1 trial

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01921387·20 enrolled

Adult1 trial

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

Completed·MMassachusetts General Hospital·Phase 1·NCT02582359·39 enrolled

Pilot Study1 trial

Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT01999413·30 enrolled

Efficacy1 trial

Efficacy of G-CSF-Priming in Elderly AML Patients

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199147·250 enrolled

Imetelstat1 trial

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recruiting·CChildren's Oncology Group·Phase 1·NCT06247787·36 enrolled

Pediatric Cancer1 trial

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Completed·—·Phase 1·NCT03654716·21 enrolled

Chidamide1 trial

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564704·80 enrolled

Induction Therapy1 trial

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting·—·Phase 2·NCT06221683·500 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Recruiting·IInstituto do Cancer do Estado de São Paulo··NCT05959720·180 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02718755

Refractory AML1 trial

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Terminated·CC. Babis Andreadis·Phase 1·NCT02109627·17 enrolled

AML1 trial

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

Completed·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT02926586·68 enrolled

Lymphoblastic Lymphoma1 trial

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting·UUniversity Hospital Muenster·Phase 3·NCT04043494·683 enrolled

Immunodeficiency1 trial

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, not recruiting·AAIDS Malignancy Consortium·Phase 1/2·NCT02797470·11 enrolled

MPR1 trial

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT02756962·107 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 21, 1987

CYTARABINE

NDA NDA016793

Apr 1, 1999

DEPOCYT

NDA NDA021041

Sources

References

[1]
ClinicalTrials.gov — 929 trial records for Cytarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Cytosar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cytarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cytarabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021041). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Cytosar

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Acute Myeloid Leukemia48 trials

Acute Lymphoblastic Leukemia30 trials

Lymphoma15 trials

Leukemia12 trials

Myelodysplastic Syndrome8 trials

Chronic Myelogenous Leukemia6 trials

Bone Marrow Transplantation6 trials

Chemotherapy5 trials

Myelodysplastic Syndromes4 trials

Newly Diagnosed4 trials

Mantle Cell Lymphoma4 trials

Stem Cell Transplant3 trials

Hematologic Malignancies3 trials

Relapse2 trials

Acute Leukemia2 trials

Treatment2 trials

Acute Promyelocytic Leukemia2 trials

Relapsed/Refractory2 trials

Stem Cell Transplantation2 trials

Diffuse Large B-Cell Lymphoma2 trials

Relapsed or Refractory2 trials

Morbidity1 trial

Graft Versus Host Disease1 trial

Acute Monocytic Leukemia1 trial

Immunotherapy1 trial

Elderly Patients1 trial

Transplantation1 trial

Efficacy and Safety1 trial

Maintenance Therapy1 trial

B-cell acute lymphoblastic leukemia1 trial

Anemia1 trial

Hematologic Cancer1 trial

Langerhans Cell Histiocytosis1 trial

ART1 trial

Relapsed AML1 trial

Myeloid Neoplasm1 trial

Hematopoietic Stem Cell Mobilization1 trial

Safety and Efficacy1 trial

Secondary AML1 trial

Graft-versus-host-disease (GVHD)1 trial

Induction Chemotherapy1 trial

Central Nervous System Lymphoma1 trial

Lymphoid Malignancies1 trial

Adult1 trial

Pilot Study1 trial

Efficacy1 trial

Imetelstat1 trial

Pediatric Cancer1 trial

Chidamide1 trial

Induction Therapy1 trial

Adult Acute Lymphoblastic Leukemia1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

Refractory AML1 trial

AML1 trial

Lymphoblastic Lymphoma1 trial

Immunodeficiency1 trial

MPR1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News